Top

memo - Magazine of European Medical Oncology

Published in:

01-05-2014 | short review

Treatment results and follow-up after definitive radio-chemotherapy in anal cancer: when to perform biopsies?

Authors: PD Dr. med. Martina Becker-Schiebe, Wolfgang Hoffmann

Published in: memo - Magazine of European Medical Oncology | Issue 2/2014

Abstract

Management of anal cancer shifted from radical surgical procedures to sphincter-preserving approaches by combined radio-chemotherapy (RCT). Several randomized trials investigated the most appropriate chemotherapy schedule, radiation doses, and treatment techniques. RCT employing 5-fluorouracil (5-FU)/mitomycin C (MMC) remains the standard treatment. Cisplatin was proposed as an alternative drug but failed to improve outcome when given instead of MMC or during maintenance chemotherapy. Currently, studies are ongoing that investigate staging procedures like PET-CT and diagnostic workup processes in treatment follow-up.

This review focuses on treatment results of definitive RCT and factors related to treatment failure. Subsequent follow-up recommendations and the timing of invasive follow-up biopsies are discussed.

Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, Mitomycin and radiotherapy vs fl uorouracil, cisplatin and radiotherapy for carcinoma of the anal canal: a randomised controlled trial. JAMA. 2008;199:1914–21.CrossRef

Ajani JA, Winter KA, Gunderson LL, et al. Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11). Cancer. 2010;116:4007–13.PubMedCrossRef

Ajani JA, Winter KA, Gunderson LL, et al. US intergroup anal carcinoma trial: tumor diameter predicts for colostomy. J Clin Oncol. 2009;27:1116–21.PubMedCentralPubMedCrossRef

Allal A, Laurencet F, Reymond M, et al. Effectiveness of surgical salvage therapy of for patients with locally uncontrolled anal cancer after sphincter conserving treatment. Cancer. 1999;86:405–9.PubMedCrossRef

Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol. 1997;15:2040–9.PubMed

Chapet O, Gerard JP, Riche B, et al. Prognostic value of tumor regression evaluated after first course of radiotherapy for anal canal cancer. Int J Radiat Oncol Biol Phys. 2005;63(5):1316–24.PubMedCrossRef

Chen Y, Yen S, Chen S, et al. Anus-preservation treatment for anal cancer: retrospective analysis at a single institution. J Surg Oncol. 2007;96:374–80.PubMedCrossRef

Cummings B, Keane T, O’Sullivan M, et al. Epidermoid anal cancer: treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin C. Int J Radiat Oncol Biol Phys. 1991;21(5):1115–25.PubMedCrossRef

Cummings BJ, Brierley JD. Anal cancer. In: Halperin EC, Perez CA, Brady LW, editors. Principles and practice of radiation oncology. 5th ed. Philadelphia:Lippincott Williams & Wilkins; 2008. pp. 1383–96.

10.

Ferrigno R, Nakamura RA, Dos Santos Novaes PE, et al. Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness. Int J Radiat Oncol Biol Phys. 2005;61:1136–42.PubMedCrossRef

11.

Flam M, John M, Pajak TF, et al. Role of mitomycin in combination with fluorouracil and radiotherapy and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol. 1996;14:2527–39.PubMed

12.

Glynne-Jones R, James R, Meadows H, et al. Optimum time to assess complete clinical response following chemoradiation using mitomycin or cisplatin with with or without maintenance cisplatin and 5 –fluorouracil in squamous cell carcinoma of the anus: Results of ACT II. J Clin Oncol. 2012;30:Suppl abst. 4004.

13.

Glynne-Jones R, Northover J, Oliveira J. Anal cancer ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20(Suppl. 4):iv57–60.

14.

Gunderson L, Moughan J, Ajani J, et al. Anal carcinoma: impact of TN category of disease on survival, disease replapse, and colostomy failure in US GI RTOG 98-11 phase 3 trial. Int J Radiat Oncol Biol Phys. 2013;87:638–45.PubMedCrossRef

15.

Gunderson LL, Winter KA, Ajani JA, et al. Long-term update of U.S. GI Intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluoruracil/cisplatin. J Clin Oncol. 2012;30:4344–51.PubMedCentralPubMedCrossRef

16.

Hughes L, Rich T, Delclos L, et al. Radiotherapy for anal cancer: experience from 1979-1978. Int J Radiat Oncol Biol Phys. 1989;17:1153–60.

17.

James R, Glynne-Jones R, Meadows H, et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. Lancet Oncol. 2013;14:516–24.PubMedCrossRef

18.

Johnson LG, Madeleine MM, Newcomer LM, et al. Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973–2000. Cancer. 2004;101:281–8.PubMedCrossRef

19.

Mai S, Welzel G, Hermann B, et al. Can the radiation dose to CT enlarged but FDG PET negative inguinal lymph nodes in anal cancer be reduced? Strahlenther Onkol. 2009;4:1–6.

20.

NCCN. National Comprehensive Cancer Network (NCCN) clinical guidelines in oncology. Anal carcinoma, version 2. National Comprehensive Cancer Network. 2013. http://www.nccn.org/professionals/physician_gls/pdf/anal.pdf. Accessed 26 March 2013.

21.

Nigro DN. Seydel HF, Facr MS, et al. Combined preoperative radiation and chemotherapy for squamous cell carcinoma ofthe anal canal. Cancer. 1983;51:1826–9.PubMedCrossRef

22.

Northover J, Glynne-Jones R, Sebag-Montefi ore D, et al. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer. 2010;102:1123–8.PubMedCentralPubMedCrossRef

23.

Rousseau DL, Thomas CR, Petrelli NJ, Kahlenberg MS. Sqamous cell carcinoma of the anal canal. Surg Oncol. 2005;14:121–32.PubMedCrossRef

24.

Sato H, Koh PK, Bartolo DCC. Management of anal canal cancer. Dis Colon Rectum. 2005;48:1301–15.PubMedCrossRef

25.

Schiebe M, Hoffmann W, Belka C, Schnauder M, Bamberg M. Mitomycin C related hemolytic uremic syndrome in cancer patients. Anticancer Drugs. 1998;9:433–35.PubMedCrossRef

26.

Schiller DE, Cummings BJ, Rai S, Le LW, Last L, Davey P, et al. Outcomes of salvage surgery for squamous cell carcinoma of the anal canal. Ann Surg Oncol. 2007;14:2780–9.PubMedCrossRef

27.

Schwarz J, Siegel B, Dehdashti F, et al. Tumor response and survival predicted by the post-therapy FDG-PET/CT in anal cancer. Int J Radiat Oncol Biol Phys. 2008;71:180–6.PubMedCrossRef

Title: Treatment results and follow-up after definitive radio-chemotherapy in anal cancer: when to perform biopsies?
Authors: PD Dr. med. Martina Becker-Schiebe
Wolfgang Hoffmann
Publication date: 01-05-2014
Publisher: Springer Vienna
Published in: memo - Magazine of European Medical Oncology / Issue 2/2014
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-014-0139-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2014

Follow-up in aggressive lymphomas

Follow-up for patients with malignancies after radical treatment: unresolved questions

Follow-up in non-small-cell lung cancer

Current therapeutic concepts in mucosa-associated lymphoid tissue (MALT) lymphoma

Follow-up in soft tissue sarcomas

Highlights in the prevention of sporadic colorectal cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer